Entropy Technologies LP Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Entropy Technologies LP trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 51.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,125 shares of the medical research company's stock after selling 5,408 shares during the period. Entropy Technologies LP's holdings in Charles River Laboratories International were worth $1,009,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its holdings in Charles River Laboratories International by 1.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company's stock worth $914,000 after purchasing an additional 45 shares in the last quarter. American Trust grew its stake in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after buying an additional 54 shares during the last quarter. Tortoise Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after acquiring an additional 57 shares during the period. OLD National Bancorp IN boosted its stake in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after buying an additional 59 shares during the period. Finally, Mitchell & Pahl Private Wealth LLC grew its stake in shares of Charles River Laboratories International by 2.0% in the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company's stock valued at $652,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. CLSA upgraded shares of Charles River Laboratories International from an "underperform" rating to a "hold" rating and set a $205.00 target price on the stock in a research report on Thursday, November 7th. JPMorgan Chase & Co. cut shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $270.00 to $205.00 in a research note on Thursday, August 8th. Finally, Bank of America cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $217.54.

Charles River Laboratories International Price Performance

NYSE CRL traded down $9.57 during trading hours on Thursday, reaching $196.97. The company's stock had a trading volume of 974,381 shares, compared to its average volume of 620,620. The firm's 50-day moving average price is $195.26 and its 200-day moving average price is $207.82. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a market capitalization of $10.07 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 5.57 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.72 earnings per share. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).